The Bellvitge Biomedical Research Institute (IDIBELL) is a biomedical research center stablished in 2004. Its stakeholders are Bellvitge University Hospital and Viladecans Hospital of the Catalan Institute of Health, the Catalan Institute of Oncology, University of Barcelona and the town council of L'Hospitalet de Llobregat
Research Group description:
How eukaryotes -including humans- inherit their nuclear genome is a fundamental question in biology which has direct clinical implications, as chromosome missegregation is a leading cause of miscarriages and birth defects, and is tightly linked to malignant tumour progression. Most aneuploid tumour cells are generated as a result of failed cytokinesis, which leads to cells containing both sets of sister chromatids. Hence, the regulation of mitosis is of paramount importance in maintaining chromosome stability. However, very little is known about mitotic exit regulation in any organism.
By studying the mechanisms that ensure completion of anaphase before cytokinesis, we hope to gain crucial insight into processes that are important for healthy growth and proliferation of all eukaryotes, including human.
Our current research is focused on the mechanisms that ensure faithful chromosome maintenance during healthy cell growth—particularly, the molecular framework responsible for the initiation of mitotic exit. We plan to extend established, state-of-the-art experimental systems using a model organism such as S. cerevisiae to study the regulation of mitosis and chromosome segregation. To address these questions we will use proteomic and genomic screens, as well as biochemical and functional studies.
For more information of the group you can visit http://www.idibell.cat/modul/cell-cycle/en.